Trends in drug resistant tuberculosis in the United States, 1993-1996

JAMA

Volumn 278, Issue 10, 1997, Pages 833-837

  Moore, Marisa ^a,b   Onorato, Ida M ^a   McCray, Eugene ^a   Castro, Kenneth G ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; GEOGRAPHIC DISTRIBUTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MODEL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; TUBERCULOSIS; UNITED STATES;

EID: 0030766237     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.278.10.833     Document Type: Article

References (28)

1. Centers for Disease Control. Strategic plan for the elimination of tuberculosis in the United States. MMWR Morb Mortal Wkly Rep. 1989;38:1-25.
2. Centers for Disease Control. National action plan to combat multidrug-resistant tuberculosis. MMWR Morb Mortal Wkly Rep. 1992;41(RR-11):1-30.
3. Mahmoudi A, Iseman MD. Pitfalls in the care of patients with tuberculosis. JAMA. 1993;270:65-68.
4. Edlin BR, Tokars JI, Grieco MH, et al. An outbreak of multidrug-resistant tuberculosis among hospitalized patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;326:1514-1521.
5. Frieden TR, Fujiwara PI, Washko RM, et al. Tuberculosis in New York City: turning the tide. N Engl J Med. 1995;333:229-233.
6. Chaulet P, Boulahbal F, Grosset J. Surveillance of drug resistance for tuberculosis control: why and how? Tuberc Lung Dis. 1995;76:487-492.
7. Doster B, Caras GJ, Snider DE. A continuing survey of primary drug resistance in tuberculosis, 1961-1968. Am Rev Respir Dis. 1976;113:419-425.
8. Centers for Disease Control. Primary resistance to antituberculous drugs - United States. MMWR Morb Mortal Wkly Rep. 1983;32:521-523.
9. Kopanoff DE, Kilburn JO, Glassroth JL, et al. A continuing survey of tuberculosis primary drug resistance in the United States. Am Rev Respir Dis. 1978;118:835-842.
10. Snider DE, Cauthen GM, Farer LS, et al. Drug resistant tuberculosis. Am Rev Respir Dis. 1991;144: 732.
11. Bloch AB, Cauthen GM, Onorato IM, et al. Nationwide survey of drug-resistant tuberculosis in the United States. JAMA. 1994;271:665-671.
12. Bloch AB, Cauthen GM, Onorato IM, et al. Drug resistant tuberculosis (TB) trends in the US. Presented at the 1994 American Lung Association/ American Thoracic Society International Conference; May 21-25, 1994; Boston, Mass.
13. Bloch AB, Onorato IM, Ihle WW, et al. Expanded tuberculosis surveillance in the United States. Public Health Rep. 1996;111:26-31.
14. Centers for Disease Control and Prevention. Laboratory practices for diagnosis of tuberculosis -United States, 1994. MMWR Morb Mortal Wkly Rep. 1995;44:587-591.
15. Burwen DR, Bloch AB, Griffin LD, et al. National trends in the concurrence of tuberculosis and acquired immunodeficiency syndrome. Arch Intern Med. 1995;155:1281-1286.
16. Small PM, Shafer RW, Hopewell PC, et al. Exogenous reinfection with multidrug-resistant Mycobacterium tuberculosis in patients with advanced HIV infection. N Engl J Med. 1993;328: 1137-1144.
17. Nardell E, McInis B, Thomas B, Weichaas S. Exogenous reinfectionwith tuberculosis in a shelter for the homeless. N Engl J Med. 1986;315:1570-1575.
18. American Thoracic Society and the Centers for Disease Control and Prevention. Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med. 1994;149:1359-1374.
19. Frieden TR, Sterling T, Pablos-Mendez A, et al. The emergence of drug-resistant tuberculosis in New York City. N Engl J Med. 1993;328:521-526.
20. Nolan CM, Williams DL, Cave MD, et al. Evolution of rifampin resistance in human immunodeficiency virus-associated tuberculosis. Am J Respir Crit Care Med. 1995;152:1067-1071.
21. Bradford WZ, Martin JN, Reingold AL, et al. The changing epidemiology of acquired drug-resistant tuberculosis in San Francisco, USA. Lancet. 1996;348:928-931.
22. Whitney CG, Ridzon R, Paul W. Epidemiology of rifampin-resistant tuberculosis (RRTB), Chicago. Am J Respir Crit Care Med. 1996;153:A492.
23. Ridzon R, Taylor J, Kelly M, et al. Increased risk of rifampin mono-resistant tuberculosis in human immunodeficiency virus infection. Am J Respir Crit Care Med. 1996;153:A493. Abstract.
24. Barnes PF. The influence of epidemiologic factors on drug resistance rates in tuberculosis. Am Rev Respir Dis. 1987;136:325-328.
25. Riley LW, Arathoon E, Loverde VD. The epidemiologic patterns of drug-resistant Mycobacterium tuberculosis: a community-based study. Am Rev Respir Dis. 1989;139:1282-1285.
26. Centers for Disease Control. Drug resistance among Indochinese refugees with tuberculosis. MMWR Morb Mortal Wkly Rep. 1981;30:273-275.
27. Laszlo A, de Kantor IN. A random sample survey of initial drug resistance among tuberculosis cases in Latin America. Bull World Health Organ. 1994;72:603-610.
28. Cohn DL, Bustreo F, Raviglione MC. Drug-resistant tuberculosis. Clin Infect Dis. 1997;24(suppl 1):S121-S130.